Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

AGM Statement

24 Jun 2014 07:00

RNS Number : 3265K
Surgical Innovations Group PLC
24 June 2014
 



 

Press Release

24 June 2014

 

 

Surgical Innovations Group plc

 

("SI" or the "Group" or the "Company")

 

AGM Statement

 

Surgical Innovations Group plc (AIM:SUN), a leading creator of innovative medical technology to address unmet clinical needs in minimally invasive surgery ('MIS'), will hold its Annual General Meeting at 2.00pm today at Clayton Wood House, 6 Clayton Wood Bank, Leeds, LS16 6QZ, during which the Chairman, Doug Liversidge CBE, will make the following statement:

 

"The Board is pleased that the Company is now succeeding in capitalising on the infrastructure put in place over the past year. We are confident that our investment choices and strategic decisions will result in future growth. Working capital has been significantly enhanced following the investment from Chris Rea, as announced on 9 June 2014 which will support the development, together with promotion, of our unique clinical solution for 3mm surgery. We look forward to welcoming Chris to the Board.

 

"We continue to build upon last year's strong growth both in the UK and US. The Resposable® concept provides a cost-saving solution to the NHS which is committed to cost reduction programs in UK hospitals. During 2013, there was a 59% increase in the number of Yorkshire hospitals using SI branded products. The US remains a key market and the Company is effectively broadening sales channels in order to realise revenue and brand recognition opportunities. This is evidenced by the 75% increase in sales to the US of SI branded products driven primarily by new dealer relationships across the US.

 

"The Board is committed to improving our manufacturing capabilities to effectively satisfy the global demand for both SI branded and OEM products. The Group is satisfied that in recent months our continued investment is being realised in this area as significant improvements have been made.

 

"The product development pipeline continues to be strengthened through the focused investment in our 3mm 'Ultra MIS' technology, underpinned by our allegiances with Key Opinion Leaders in this specific surgical field. The Board is confident that the Group's future success will be achieved through the strategic introduction of our '3mm 'Ultra MIS' clinical solutions.

 

"Overall, we are pleased with the progress made and look to the future with confidence."

 

-Ends-

 

For further information please contact:

Surgical Innovations Group plc

Graham Bowland, Chief Executive Officer

Mike Thornton, Chief Financial Officer

Tel: +44 (0) 113 230 7597 www.sigroupplc.com

Nominated Advisor and Broker

Panmure Gordon

Freddy Crossley (Corporate Finance)

Maisie Atkinson (Corporate Broking)

Tel: +44 (0) 207 886 2500

www.panmure.com

Media Enquiries

Abchurch Communications

Sarah Hollins / Jamie Hooper / Stephanie Watson

surgical@abchurch-group.com

Tel: +44 (0) 207 398 7716

www.abchurch-group.com

 

 

 

Notes to Editors:

Surgical Innovations Group plc (AIM: SUN) is a highly reputable British-based medical device designer and manufacturer, focused on delivering innovative clinical solutions for surgeons that are both cost-effective and efficient. Since the Group's inception in 2002, its foundations have been rooted in the field of laparoscopic surgery. It has established itself as pioneers in this field and successfully developed a portfolio of innovative medical instrumentation for Minimally Invasive, or "Key-Hole", Surgery.

 

Surgical Innovations' industry leading products are centered on its pioneering "Resposable™" concept which utilises a combination of disposable and reusable components to deliver cost-efficient solutions to healthcare organisations which, in this time of financial austerity, constantly have to find budget saving alternatives that do not compromise treatment quality. Within the Group's SI Brand division, the portfolio of products includes port access systems, instrumentation and retraction devices. Not only do such devices supply the laparoscopic market, the technologies can also be transferred in to other areas of the body such as hip arthroscopy, cardiac and thoracic. Additionally the Company is also exploring alternative therapeutic avenues and thus generating additional revenue streams. It has also successfully taken its technology to the industrial sector, and can currently conduct keyhole surgery on jet engines.

 

The business has a compelling market position with an established international footprint. Through its developed network of distribution partners, Surgical Innovations' branded products are being sold in all the major high growth medical device markets, including: UK, US, South East Asia, Australasia and the Indian subcontinent. With an investment strategy focused on Sales and Marketing, the Group is well positioned and has the management expertise in place to capitalise on the growing demand, gain market share and deliver return to shareholders.

 

For more information, please see www.sigroupplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSEEFUDFLSELM
Date   Source Headline
27th Sep 20193:40 pmRNSExercise of Options, Issue of Equity and TVR
17th Sep 20197:00 amRNSHalf-year Report
3rd Sep 20197:00 amRNSNotice of Results
19th Jun 20194:03 pmRNSResult of AGM
19th Jun 20197:00 amRNSBoard and management structure changes
7th Jun 20197:00 amRNSTrading Update
6th Jun 20192:00 pmRNSHolding(s) in Company
29th May 20193:06 pmRNSExercise of Options, PDMR Shareholding & TVR
23rd May 201910:38 amRNSHolding(s) in Company
22nd May 201910:16 amRNSHolding(s) in Company
13th May 20196:25 pmRNSNotification of Major Interest in Shares
27th Mar 20197:00 amRNSGrant of Options
15th Mar 20194:27 pmRNSDirector/PDMR Shareholding
12th Mar 20197:00 amRNSFinal Results
28th Feb 20196:18 pmRNSExercise of Options & Total Voting Rights
28th Feb 20197:00 amRNSAppointment of CEO & changes in senior management
27th Feb 20197:00 amRNSNotice of Results
20th Feb 20197:00 amRNSUpdate on contingency planning for no-deal Brexit
14th Jan 20197:00 amRNSYear-end Trading Update
3rd Dec 20187:00 amRNSAppointment of Nominated Adviser and Broker
6th Nov 20187:00 amRNSSurgical robot technology UK distribution deal
16th Oct 201810:53 amRNSDirector/PDMR Shareholding
13th Sep 20187:00 amRNSCE mark certification obtained for CELLIS range
11th Sep 201810:23 amRNSDirector/PDMR Shareholding
11th Sep 20187:00 amRNSHalf-year Report
29th Aug 20187:00 amRNSCE mark validation indicated for CELLIS range
22nd Aug 20187:00 amRNSNotice of Results
26th Jun 20184:41 pmRNSResult of AGM
26th Jun 20187:00 amRNSAGM Statement
4th Jun 201811:34 amRNSHolding(s) in Company
25th May 20187:00 amRNSTrading Update
23rd Mar 20183:25 pmRNSDirector/PDMR Shareholding
13th Mar 20183:06 pmRNSDirector/PDMR Shareholding
13th Mar 20187:00 amRNSFinal Results
28th Feb 20187:00 amRNSDistribution agreement via Elemental Healthcare
19th Feb 20187:01 amRNSDistribution agreement via Elemental Healthcare
19th Feb 20187:00 amRNSNotice of Results
11th Jan 20187:00 amRNSYear-end trading update
21st Dec 201712:15 pmRNSIssue of Shares
15th Nov 201711:47 amRNSDirector/PDMR Shareholding
6th Nov 20177:00 amRNSDirector/PDMR Shareholding
31st Oct 201710:58 amRNSDirector/PDMR Shareholding
31st Oct 20177:00 amRNSGrant of Options
30th Oct 20172:33 pmRNSIssue of Equity
10th Oct 20173:36 pmRNSIssue of Equity
26th Sep 201712:28 pmRNSIssue of Equity
22nd Sep 20178:55 amRNSHolding(s) in Company
13th Sep 20177:00 amRNSHalf-year Report
10th Aug 20177:00 amRNSNotice of Results
4th Aug 201712:32 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.